The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study

Gonzalo Sapisochin, Nicolas Goldaracena, Jerome M. Laurence, Martin Dib, Andrew Barbas, Anand Ghanekar, Sean P. Cleary, Les Lilly, Mark S. Cattral, Max Marquez, Markus Selzner, Eberhard Renner, Nazia Selzner, Ian D. McGilvray, Paul D. Greig, David R. Grant – 14 May 2016 – The selection of liver transplant candidates with hepatocellular carcinoma (HCC) relies mostly on tumor size and number. Instead of relying on these factors, we used poor tumor differentiation and cancer‐related symptoms to exclude patients likely to have advanced HCC with aggressive biology.

The case for immune‐based approaches in biliary tract carcinoma

Austin G. Duffy, Oxana V. Makarova‐Rusher, Tim F. Greten – 14 May 2016 – Biliary tract cancers (BTC) comprise a group of uncommon malignancies in which the standard therapies are minimally effective and evolve slowly. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune‐based approaches has yet to be seen. However, the etiological background of BTC—overlapping in almost every known causative or associated factor with inflammation—provides a strong clue that these approaches may have an impact in this group of diseases.

Exosome‐mediated activation of toll‐like receptor 3 in stellate cells stimulates interleukin‐17 production by γδ T cells in liver fibrosis

Wonhyo Seo, Hyuk Soo Eun, So Yeon Kim, Hyon‐Seung Yi, Young‐Sun Lee, Seol‐Hee Park, Mi‐Jin Jang, Eunjung Jo, Sun Chang Kim, Yong‐Mahn Han, Keun‐Gyu Park, Won‐Il Jeong – 14 May 2016 – During liver injury, hepatocytes secrete exosomes that include diverse types of self‐RNAs. Recently, self‐noncoding RNA has been recognized as an activator of Toll‐like receptor 3 (TLR3). However, the roles of hepatic exosomes and TLR3 in liver fibrosis are not yet fully understood.

Medicaid enrollment after liver transplantation: Effects of medicaid expansion

Dmitry Tumin, Don Hayes, W. Kenneth Washburn, Joseph D. Tobias, Sylvester M. Black – 6 May 2016 – Liver transplantation (LT) recipients in the United States have low rates of paid employment, making some eligible for Medicaid public health insurance after transplant. We test whether recent expansions of Medicaid eligibility increased Medicaid enrollment and insurance coverage in this population.

Perioperative prostaglandin e1 infusion in living donor liver transplantation: A double‐blind, placebo‐controlled randomized trial

Viju Kumar Bharathan, Biju Chandran, Unnikrishnan Gopalakrishnan, Christi Titus Varghese, Ramachandran N. Menon, Dinesh Balakrishnan, O. V. Sudheer, Puneet Dhar, Sudhindran Surendran – 6 May 2016 – The role of prostaglandin E1 (PGE1) infusion in improving early graft function has not been well defined, especially in the scenario of living donor liver transplantation (LDLT). We designed a randomized, double‐blind, placebo‐controlled trial to evaluate the role of perioperative PGE1 infusion in LDLT.

Subscribe to